Search Results

BioMidwest

Sigma-Aldrich and Genoway Expand Their CRISPR/CAS9 Strategic Alliance

Sigma-Aldrich Co LLC and genOway announced a new structure to their 2018 strategic alliance in the CRISPR/Cas9 field.

September 8, 2022

·

3 min read

genOway grants the leading UK academic research funder a non-exclusive license for CRISPR/Cas9 technology

genOway, a world leader in the field of genetically modified innovative research models, announced that it has granted a non-exclusive CRISPR/Cas9 license to the most important funding institution of biomedical academic research in the United Kingdom.

January 25, 2022

·

2 min read

genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models

genOway, a public company and leader in developing genetically modified research models, today announced an important milestone in extending its strategic alliance with Merck, a leading science and technology company and leader in genome editing.

January 7, 2020

·

2 min read

Business

MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models

MilliporeSigma, a leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.

December 10, 2018

·

6 min read

Animal Model Market Share, Growth, Top Industry Players Envigo, Eurofins Scientific SE, GenOway S.A., JSR Corporation

Increase in usage of animal models in virology and infectious diseases, rise in adoption of CRISPR technology, and upsurge in likelihood of epidemic or pandemic outbreaks fuel the growth of the global animal model market.

August 25, 2021

·

4 min read

Genetown

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a peer-reviewed research paper in Nature Communications.

April 4, 2024

·

5 min read

Business

genOway Offers Industry Scientists Immediate Access To EUCOMM Conditional KO Mouse Models

July 2, 2014

·

6 min read

Drug Development

Cellectis Grants genOway An Exclusive Sublicense For Its Homologous Recombination Technology In The Field Of Genetically Modified Rodent Models

February 4, 2014

·

5 min read

Business

CELLECTIS SA And genOway Close Their Disagreement

February 18, 2010

·

2 min read

Policy

CELLECTIS SA Rectifies genOway’s Statements

November 18, 2009

·

2 min read